Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 3Withdrawn 2Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Genitourinary 2Breast 2Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1

Interventions

Rituximab 55Cyclophosphamide 45Vincristine 23fludarabine phosphate 21Cytarabine 20fludarabine 19Etoposide 19Prednisone 18Bendamustine Hydrochloride 18ibrutinib 17Methotrexate 17Doxorubicin 17Lenalidomide 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 12venetoclax 11Melphalan 11Dexamethasone 11Whole-Body Irradiation 8Tacrolimus 8Busulfan 8Brentuximab Vedotin 8Biopsy 8pembrolizumab 7duvelisib 7Nivolumab 7Mycophenolic Acid 7Gemcitabine 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × antineoplaston A10 × Lymphoid × Clear all
NCT00003512 2018-02-05

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Burzynski Research Institute

Phase 2 Withdrawn
Lymphoid

Waldenstrom Macroglobulinemia

NCT00003502 2013-07-10

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡